Quick Answer
Aldeyra Therapeutics, Inc. reported Stockholders Equity of $44.25 million for the year ending 2025.
- Aldeyra Therapeutics, Inc. showed a decrease of -37.7% in Stockholders Equity from 2024 to 2025.
- This data is from Aldeyra Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2004: $947.00 | Q4 2005: -$385.2 thousand | Q4 2006: -$1.32 million | Q4 2007: -$1.85 million | Q4 2008: -$4.06 million | Q4 2009: -$9.21 million | Q4 2010: -$12.97 million | Q4 2011: -$15.51 million | Q1 2014: -$39.65 million | Q2 2014: $9.81 million | Q3 2014: $8.26 million | Q1 2015: $13.83 million | Q2 2015: $31.52 million | Q3 2015: $28.70 million | Q1 2016: $20.53 million | Q2 2016: $29.52 million | Q3 2016: $25.67 million | Q1 2017: $28.00 million | Q2 2017: $23.34 million | Q3 2017: $45.90 million | Q1 2018: $36.00 million | Q2 2018: $36.98 million | Q3 2018: $28.60 million | Q1 2019: $78.48 million | Q2 2019: $67.33 million | Q3 2019: $50.88 million | Q1 2020: $43.47 million | Q2 2020: $52.79 million | Q3 2020: $69.17 million | Q1 2021: $126.07 million | Q2 2021: $233.68 million | Q3 2021: $219.67 million | Q1 2022: $190.69 million | Q2 2022: $174.03 million | Q3 2022: $162.19 million | Q1 2023: $137.24 million | Q2 2023: $129.88 million | Q3 2023: $123.01 million | Q1 2024: $113.42 million | Q2 2024: $98.31 million | Q3 2024: $85.10 million | Q1 2025: $63.60 million | Q2 2025: $55.29 million | Q3 2025: $49.24 million.
- Over the full 14 years of available data (2012 to 2025), Aldeyra Therapeutics, Inc.'s Stockholders Equity has grown by 181.4%.
- Historical annual values: Fiscal year 2025: $44.25 million | Fiscal year 2024: $71.00 million | Fiscal year 2023: $119.80 million | Fiscal year 2022: $151.01 million | Fiscal year 2021: $205.74 million | Fiscal year 2020: $59.51 million | Fiscal year 2019: $48.08 million | Fiscal year 2018: $86.62 million | Fiscal year 2017: $39.60 million | Fiscal year 2016: $21.65 million | Fiscal year 2015: $24.88 million | Fiscal year 2014: $6.28 million | Fiscal year 2013: -$40.22 million | Fiscal year 2012: -$54.38 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: